Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16-Reference-Cited by-同舟云学术

Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16

Published:2006-04-19 Issue:8 Volume:98 Page:516-521
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Petrylak Daniel P.,Ankerst Donna Pauler,Jiang Caroline S.,Tangen Catherine M.,Hussain Maha H. A.,Lara Primo N.,Jones Jeffrey A.,Taplin Mary Ellen,Burch Patrick A.,Kohli Manish,Benson Mitchell C.,Small Eric J.,Raghavan Derek,Crawford E. David

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/98/8/516/7688547/djj129.pdf

Reference16 articles.

1. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med1998 ; 339 : 1036 –42.

2. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol1993 ; 11 : 607 –15.

3. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol1998 ; 16 : 1835 –43.

4. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol1999 ; 17 : 3461 –7.

5. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med1989 ; 8 : 431 –4.

Cited by 262 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial;European Urology;2024-09

2. Fluorine-18 prostate-specific membrane antigen-1007-avid indeterminate bone lesions in prostate cancer: clinical and PET/CT features to predict outcomes and prognosis;Clinical Radiology;2024-05

3. Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer;Journal of Clinical Medicine;2023-08-28

4. Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer;Clinical Cancer Research;2023-03-30

5. Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer;NEJM Evidence;2023-03-28